- Trials with a EudraCT protocol (11)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
11 result(s) found for: low dose naltrexone.
Displaying page 1 of 1.
EudraCT Number: 2015-002972-26 | Sponsor Protocol Number: LDN_7323 | Start Date*: 2015-12-14 | |||||||||||
Sponsor Name:Smerteklinikken | |||||||||||||
Full Title: Low dose naltrexone for treatment of pain in patients with fibromyalgia - effect via central mechanism? A randomized, double-blinded, placebo-controlled, cross-over study | |||||||||||||
Medical condition: Pain in patients with fibromylagia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-005679-13 | Sponsor Protocol Number: NALTREX005 | Start Date*: 2006-06-28 | |||||||||||
Sponsor Name:OSPEDALE S. RAFFAELE | |||||||||||||
Full Title: An open-label, prospective, multicentric pilot study evaluating safety and symptomatics effects of low dose Naltrexone in patients with primary progressive multiple sclerosis. | |||||||||||||
Medical condition: multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002081-31 | Sponsor Protocol Number: 16008 | Start Date*: 2016-11-17 | |||||||||||
Sponsor Name:Anæstesiologisk-intensiv afd V, Odense Universitets Hospital | |||||||||||||
Full Title: Investigation of dose response relationships when using low dose naltrexone (LDN) for the treatment of fibromyalgia | |||||||||||||
Medical condition: Fibromyalgia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000702-30 | Sponsor Protocol Number: 18.021 | Start Date*: 2019-10-30 | |||||||||||
Sponsor Name:Odense University Hospital | |||||||||||||
Full Title: Fibromyalgia and Naltrexone: The FINAL study | |||||||||||||
Medical condition: Fibromyalgia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000852-32 | Sponsor Protocol Number: 80-84800-98-82002 | Start Date*: 2020-01-30 |
Sponsor Name:ErasmusMC | ||
Full Title: A preliminary study of Low Dose Naltrexone for the induction of remission in patients with mild to moderate Crohn’s Disease that failed conventional treatment: The LDN Crohn study. | ||
Medical condition: Inflammatory Bowel Disease, Crohn's disease | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2022-000245-33 | Sponsor Protocol Number: VN21 | Start Date*: 2022-05-31 | |||||||||||
Sponsor Name:Medical University of Lublin | |||||||||||||
Full Title: To evaluate the effect of low-dose naltrexone (LDN) on pain perception and quality of life in women | |||||||||||||
Medical condition: Vulvodynia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: PL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002534-16 | Sponsor Protocol Number: FSJD-INNOVA-2020 | Start Date*: 2021-10-15 | |||||||||||
Sponsor Name:Fundació Sant Joan de Déu | |||||||||||||
Full Title: 12-month randomized, double-blind, placebo-controlled, pharmacological clinical trial to evaluate the effectiveness, cost-utility and neurobiological effects of low-dose Naltrexone in patients with... | |||||||||||||
Medical condition: Fibromyalgia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-004273-10 | Sponsor Protocol Number: 3200L2-300-WW | Start Date*: 2007-01-08 |
Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc. | ||
Full Title: A multicenter, randomized, double-blind, placebo-controlled, parallel-group study of intravenous Methylnaltrexone (MOA-728) for the treatment of post operative ileus | ||
Medical condition: Post operative ileus (POI) in patients who have had a segmental colectomy via open laparotomy. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) CZ (Completed) IT (Completed) HU (Completed) | ||
Trial results: View results |
EudraCT Number: 2022-002695-37 | Sponsor Protocol Number: CLIN-60190-453 | Start Date*: 2023-04-27 | |||||||||||
Sponsor Name:Ipsen Bioscience, Inc. | |||||||||||||
Full Title: A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open-Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants with Primary ... | |||||||||||||
Medical condition: Adults patients with Primary Sclerosing Cholangitis (PSC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) ES (Ongoing) PT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004941-34 | Sponsor Protocol Number: GFT505B-319-1 | Start Date*: 2020-10-09 | |||||||||||
Sponsor Name:IPSEN Pharma SAS | |||||||||||||
Full Title: A Double-blind Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients with Primary Biliary Cholangitis with Ina... | |||||||||||||
Medical condition: Primary Biliary Cholangitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004431-79 | Sponsor Protocol Number: CC-90001-NASH-001 | Start Date*: 2019-11-15 |
Sponsor Name:Celgene Corporation | ||
Full Title: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, DOSEFINDING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-90001 IN SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) AND LIVE... | ||
Medical condition: Confirmed diagnosis of NASH and Stage 3 or Stage 4 fibrosis based upon the NASH Clinical Research Network (CRN) Histologic Scoring System and a nonalcoholic fatty liver disease (NAFLD) Activity Sco... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) FR (Prematurely Ended) ES (Ongoing) PL (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
